Originally published In Press as doi:10.1074/jbc.C100388200 on October 18, 2001
J. Biol. Chem., Vol. 276, Issue 49, 46480-46484, December 7, 2001
Human Sex Reversal Due to Impaired Nuclear
Localization of SRY
A CLINICAL CORRELATION*
Biaoru
Li,
Wei
Zhang,
Ging
Chan,
Agnes
Jancso-Radek
,
Shunhe
Liu, and
Michael A.
Weiss§
From the Department of Biochemistry, Case Western Reserve
University, School of Medicine, Cleveland, Ohio 44106
Received for publication, July 10, 2001, and in revised form, October 12, 2001
 |
ABSTRACT |
SRY, an architectural transcription factor
encoded by the sex-determining region of the Y chromosome, initiates
testicular differentiation in mammalian embryogenesis. The protein
contains a high-mobility group (HMG) box, a DNA-bending motif conserved among a broad class of nuclear proteins. Mutations causing human sex
reversal (46, XY pure gonadal dysgenesis) are clustered in this domain.
Basic N- and C-terminal regions of the HMG box are each proposed to
provide nuclear localization signals. The significance of the
C-terminal basic cluster (SRY residues 130-134) is uncertain, however,
as its activity in cell culture varies with assay conditions. To test
its importance, we have investigated a C-terminal sex-reversal mutation
(R133W, position 78 of the HMG box). This de novo mutation impairs nuclear localization but not specific DNA binding or sharp DNA
bending. Correlation between these properties and the phenotype of the
patient suggests that nuclear localization of SRY is required for
testicular differentiation and directed in part by the
C-terminal basic cluster. To our knowledge, these results provide the
first example of impaired organogenesis due to a nuclear localization signal mutation.
 |
INTRODUCTION |
SRY, the testes-determining factor encoded by the human Y
chromosome (1), contains a high-mobility group
(HMG)1 box (2-4), a
conserved motif of DNA bending (Fig. 1, A and C, and Ref. 5). Mutations in SRY are associated with 46, XY pure gonadal
dysgenesis leading to failure of testicular differentiation and female
somatic phenotype (XY sex reversal; Refs. 3 and 6-8). Clinical
mutations cluster in the HMG
box2 and most commonly impair
specific DNA binding (7, 9, 10). SRY is a nuclear protein (11)
expressed in the primordial Sertoli cells of the differentiating
gonadal ridge (12-14). Although SRY is presumed to function as an
architectural transcription factor (9, 15, 16), its downstream genetic
pathway is not well characterized (for a review, see Ref. 17).
Immunohistochemical studies of murine and human embryos have
demonstrated that SRY is a nuclear protein (11, 18). Nuclear localization signals (NLSs) in human SRY have been defined in cell
culture. Berta and colleagues (11), using microinjection of proteins in
adult human fibroblastic cells, identified an NLS in the N-terminal
region of the human HMG box3
(Fig. 2A; SRY residues 59-75). This NLS comprises two sets
of basic amino acids separated by 12 residues (Fig. 2B),
features characteristic of bipartite NLS motifs in diverse proteins
(19, 20). An isolated N-terminal SRY peptide (residues 58-78) was shown to be sufficient to direct nuclear translocation of coupled rabbit IgG (protein SRY21 in Fig. 2A). By contrast the
remainder of the HMG box (residues 74-137) was unable to direct
nuclear translocation of coupled rabbit IgG (protein SRY64 in Fig.
2A). Although these findings appear to exclude a second NLS
in SRY, Südbeck and Scherer (21) subsequently used a
complementary methodology (transient transfection of
SRY-
-galactosidase fusion genes in COS-7 cells; Fig. 2B)
to identify a basic cluster NLS (residues 130-134;
underlined in Fig.
1B, top sequence)
in the C-terminal tail of the HMG box (highlighted in red in
Fig. 1, A-C). Whereas the microinjection assay suggested
that the N-terminal NLS is sufficient to direct complete nuclear
localization, in the transient transfection assay both N- and
C-terminal NLS motifs are required (21). These differences may be due
to assay procedures and/or cell
lines.4 The function of the
NLSs of SRY has not been established in vivo as to date no
clinical mutations have been shown to impair nuclear localization.

View larger version (49K):
[in this window]
[in a new window]
|
Fig. 1.
Structure of SRY HMG box and SRY·DNA
complex. A, ribbon model of SRY HMG box (10) and
position of disordered tail (red dashed line). Selected
conserved side chains are shown, labeled according to the HMG box
consensus sequence. B, alignment of C-terminal basic
sequences (residues 120-140 in SRY and residues 65-85 in HMG box
consensus sequence). The upper group contains mammalian SRY
sequences (h, human; m, mouse; b,
bovine; g, goat; e, elephant; p, pig;
and o, ovine); the lower group contains related
sequences of Lef-1 and T-cell factor 1 (TCF1). Open
circles denote structurally important side chains; closed
circles indicate DNA contacts. The asterisk
(red) indicates the site of R133W sex-reversal mutation;
Y127C mutation is also shown. The arrow denotes the site of
truncation in the SRY fragment used in structural studies (10). The
five underlined residues indicate the previously
characterized deletion (residues 130-134; construction SRY-D3 in Ref.
21) used as a control for loss of C-terminal NLS activity.
C, structure of specific SRY·DNA complex (10) showing HMG
box (white ribbon), C-terminal basic tail containing
putative NLS (red), and DNA site (green). The
tail terminates at residue 75 due to disorder of residues
76-78.
|
|
In this communication we provide evidence for the physiological
importance of the putative C-terminal NLS. Experimental design exploits
a de novo sex-reversal mutation in the C-terminal basic cluster (R133W; Fig. 1B and Ref. 22) to distinguish between DNA binding and nuclear localization. The site of mutation is disordered in the NMR structure of a specific SRY·DNA complex (Fig. 1C and Ref. 10). Although the variant SRY domain
exhibits essentially native DNA recognition, the mutation impairs
nuclear translocation in a rat embryogenic gonadal ridge cell line.
Control substitution R133A also impairs NLS function, suggesting that mislocalization is due to loss of the native side chain rather than
specific interference by tryptophan. Correlation between impaired
nuclear localization and phenotype (XY sex reversal) strongly suggests
that the C-terminal basic cluster contributes to the nuclear
localization of SRY in vivo and that such localization is
required for testicular differentiation. To our knowledge, this is the
first example of impaired organogenesis associated with mutation of an
NLS.
 |
EXPERIMENTAL PROCEDURES |
Protein Purification
Native and variant SRY HMG box domains (84 amino acid; residues
57-140) were expressed in Escherichia coli as
thrombin-cleavable fusion proteins and purified as described previously
(23). The final SRY fragment (86 residues) contains two additional
N-terminal residues (Gly-Ser) derived from the thrombin site. Purity
was >98% as assessed by SDS-polyacrylamide gel electrophoresis and reverse-phase high-performance liquid chromatography. Predicted molecular masses of SRY fragments were verified by mass spectrometry.
Circular Dichroism
Spectra were obtained using an Aviv spectropolarimeter in 50 mM KCl and 10 mM potassium phosphate (pH 7.4)
as described previously (24).
DNA Binding Studies
The sequence specificity of the SRY HMG box has previously been
described (6, 7, 9, 10, 23). For use in the gel mobility shift assay
(GMSA), a 15-bp DNA probe (23) was prepared containing sequence
5'-GTGATTGTTCAG-3' and complement (core target site in
bold). The probe was labeled with 33P and annealed. Each
reaction contained 6.25-50 nM protein (see caption to Fig.
2C) and <1 nM labeled DNA in 10 mM
potassium phosphate (pH 7.0), 50 ng/ml bovine serum albumin, 50 mM KCl, 4 mM dithiothreitol, and 2.5 mM MgCl2; the reaction was incubated for 1 h on ice. In control GMSA studies using a heterologous DNA target site
(phage
operator site OL1; 17 bp) the SRY HMG
box did not form a shifted band. Gels were repeated in triplicate.
DNA Bending Studies
For permutation gel electrophoresis (PGE), DNA probes of equal
length (147 bp) with an SRY binding site (5'-GTGATTGTTCAG-3' and complement) at varying distance from ends (distances of bend center
from 5'-end are 120, 95, 79, 51, 47, and 27 bp) were generated by
polymerase chain reaction from vector pBend2 as described previously (25) and 5'-labeled with [33P]ATP using T4 polynucleotide
kinase. 10-µl binding reactions contained 50 mM KCl, 20 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 20 ng of poly(dI-dC), 400 ng of bovine serum albumin, 10% glycerol, ~1
nM 33P-labeled DNA probe, and 200 nM protein. After incubation on ice, samples were run on a
10% polyacrylamide gel (with 29:1 ratio bisacrylamide) in 0.5× (0.045 M) Tris borate buffer containing EDTA (TBE) at
10 V/cm.
Gels were repeated in triplicate. Induced DNA bend angles were
calculated as described previously (26). In multiple PGE studies of the
wild-type protein inferred DNA bend
angles5 were in general
±1°. Wild-type and variant proteins were run on the same gel.
Optical Microscopy
Confocal analysis was performed using a Zeiss LSM-410 laser
scanning confocal microscope equipped with barrier filter for fluorescein (argon 488 nm as light source). An ×40 oil-immersion objective (numerical aperture, 1.3) was used for imaging of
fluorescently labeled samples. Images were captured from the confocal
optical section. Image analysis was performed using vendor software.
Cell Culture
COS-7 (American Type Culture Collection) and CH34 cell lines
(kindly provided by Prof. P. K. Donahoe, Massachusetts General Hospital, Boston, MA) were cultured in 12-well plates at 60%
confluency in Dulbecco's modified Eagle's medium containing 5%
heat-inactivated fetal bovine serum and 1× penicillin/streptomycin
(Life Technologies, Inc.) at 37 °C under 5% CO2.
Cellular Localization Studies
Constructions SRY-WT and pSRY-D3 (Fig. 2B) were
kindly provided by Dr. Gerd Scherer (Institute of Human Genetics,
University of Freiburg, Germany). SRY-R133W and SRY-R133A were obtained
from SRY-WT by site-directed mutagenesis using the
QuikChangeTM kit (Stratagene, Inc.). Transfections were
performed using LipofectAMINETM2000 kit (Life Technologies,
Inc). Following transfection, fresh Dulbecco's modified Eagle's
medium containing 5% heat-inactivated fetal bovine serum and 1×
penicillin/streptomycin was added. Cells were evaluated after 48 h
by 5-bromo-4-chloro-3-indolyl-
-D-galactosidase (X-gal)
staining or immunohistochemistry as follows.
Enzymatic Staining--
Cells were fixed with 4%
paraformaldehyde in phosphate-buffered saline (PBS) for 15 min and
stained for 2 h with X-gal as described by the vendor (Invitrogen,
Inc.).
Immunocytochemistry for Fixed Cells--
Cells were fixed with
3.5% formaldehyde in PBS on ice for 20 min, treated with successive
ethanol solutions at
20 °C (70% ethanol for 7 min, 100% ethanol
for 7 min, and 70% ethanol for 5 min), incubated for 45 min with
anti-
-galactosidase antibody (at 1:100 dilution), and incubated for
45 min with fluorescein isothiocyanate-conjugated anti-mouse antibody
(at 1:500 dilution). Antisera were obtained from Molecular Probes, Inc.
(Eugene, OR). After two PBS washes, specimens were observed by LSM 410 confocal microscopy.
Live Labeling--
Cells at 37 °C were treated with 1 mM 5-chloromethylfluorescein-di-
-galactopyranoside
(CMFDG) in hypertonic loading medium at 37 °C for 10 min and
incubated in hypotonic loading medium for 2 min and culture medium
for 30 min.
Statistical Analysis
The Pearson correlation method was used to assess possible
pairwise relationships. A p value of less than 0.05 (two-tailed) was used as a threshold for statistical significance.
Analysis used data obtained from the two fixed-cell assays.
 |
RESULTS |
DNA Binding Studies--
Effects of the R133W mutation on
structure, DNA binding, and DNA bending were evaluated in an SRY domain
containing the HMG box and C-terminal tail (residues 56-140). CD
spectra of native and variant domains are indistinguishable (data not
shown). The mutation has no detectable effect on specific DNA binding
as evaluated using the GMSA (Fig.
2C). Likewise, native and
variant domains induce similar anomalies in permutation gel
electrophoresis (Fig. 2D). The dependence of electrophoretic
mobility on flexure displacement corresponds to apparent DNA bend
angles of 79° and 73°, respectively. Although these values are
model-dependent (26), the data indicate that the variant
domain retains sharp DNA bending activity. Its small difference in bend
angle, although of biophysical interest (see "Discussion"), would
not be associated with attenuation of transcriptional activation or
repression by homologous HMG box factors (27, 28).

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 2.
Experimental design and DNA binding
studies. A, summary of microinjection studies of Berta
and co-workers (11). The rectangle denotes SRY; the
shaded region is the HMG box. Microinjected proteins SRY80,
SRY64, and SRY21 are outlined in schematic form. The panel is adapted
from Ref. 11. B, summary of transient transfection studies
of Südbeck and Scherer (21). The rectangle denotes the
SRY- -galactosidase fusion gene; the shaded region is the
HMG box. Transfected constructions SRY-WT, SRY-R133W, SRY-R133A, and
SRY-D3 are outlined in schematic form. Bipartite and basic cluster NLS
sequences are shown; basic residues are underlined. The
asterisk indicates residue 133. The panel is adapted from
Ref. 21. C and D, native and R133W variant SRY
domains exhibit similar DNA binding and DNA bending properties.
C, GMSA studies of specific DNA binding of wild-type SRY
domain and R133W variant domain (R78W in HMG box consensus sequence;
see Fig. 1A). The DNA probe (15 bp) contains SRY consensus
target site 5'-ATTGTT-3' and complement (see "Experimental
Procedures"). Free DNA probe is shown in lane 9. Protein
concentrations are: 6.25 nM (lanes 1 and
5), 12.5 nM (lanes 2 and
6), 25 nM (lanes 3 and 7),
and 50 nM (lanes 4 and 8).
c1 indicates specific 1:1 complex; c2 indicates a
higher order complex (60). D, PGE studies of wild-type and
variant bent DNA complexes. Inferred DNA bend angles are 79° and
73°, respectively. Small differences are observed in mobilities of
free probes, presumably due to permutation of intrinsic DNA-bending
sequences. Lanes a-f indicate DNA probes with target site
placed 120, 95, 79, 51, 47, and 27 bp from 5'-end,
respectively.
|
|
Nuclear Localization--
Studies used an SRY-
-galactosidase
fusion plasmid (kindly provided by G. Scherer; Ref. 21). In accord with
previous studies SRY directs nuclear localization of
-galactosidase
enzymatic activity (Fig. 3, A
and B, column 1; Refs. 11 and 21). A previously characterized five-residue deletion in the C-terminal basic cluster (residues 130-134; construction SRY-D3 in Fig. 2B; Ref. 21) was used as a control for loss of C-terminal NLS activity. Transient transfection experiments were performed using COS-7 cells to enable comparison with the results of Südbeck and Scherer (21) and a
male rat gonadal ridge embryogenic cell line (CH34 cells; Refs. 9 and
29) to provide a physiologically appropriate milieu. Cellular
localization of
-galactosidase was quantitatively evaluated by two
complementary methods: staining of fixed cells using X-gal (rows
a and a' in Fig. 3, A and B,
respectively) and confocal immunofluorescence analysis of fixed cells
(rows b and b'). To obtain meaningful statistics,
~100 cells were counted by X-gal staining, and ~20-50 fixed cells
were visualized by confocal microscopy. Representative images are shown
in Fig. 3. As a control for possible confounding factors related to
cell fixation, live labeling and confocal immunofluorescence analysis
of transfected cells were used to verify our interpretation of
subcellular localization (rows c and c').

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 3.
Studies of SRY nuclear localization in cell
culture. A, row a, X-gal staining of
transfected fixed COS-7 cells highlighting localization of
-galactosidase activity in constructions containing wild-type SRY
(wt), clinical mutation (R133W), alanine substitution
(R133A), and positive control (pSRY-D3 (D3 control)).
Constructions are outlined in Fig. 2B. Row b,
confocal and immunofluorescence analysis of fixed COS-7 cells incubated
with anti- -galactosidase antibody and fluorescein
isothiocyanate-conjugated anti-mouse antibody. Row c, live
labeling and confocal analysis of cells expressing
SRY- -galactosidase fusion proteins in COS-7 transfected cell
line. In all three studies the R133W mutation, R133A substitution, and
positive control exhibit significant localization of -galactosidase
activity in both cytoplasm and nucleus rather than predominantly in the
nucleus as in wild type. B, rows a',
b', and c', same studies as above in CH34 gonadal
ridge cell line (9, 29).
|
|
Control construction SRY-WT directs exclusive nuclear localization of
-galactosidase in ~90% of COS-7 cells (114 of 127 cells counted)
or CH34 cells (115 of 123 cells counted) (Fig. 3, column 1),
whereas SRY-D3 yields a broad distribution of
-galactosidase in the
nucleus and cytoplasm in >95% of COS-7 cells (108 of 111 cells
counted) and ~80% of CH34 cells (124 of 154 cells counted) (Fig. 3,
column 4). Similar results were obtained by the
immunohistochemical assay. Like the SRY-D3 negative control, R133W and
R133A constructions (Fig. 3, columns 2 and 3, respectively)
gave rise to pancellular distribution in more than 80% of cells
analyzed by either assay.
-Galactosidase staining in COS-7 cells was
pancellular in 83 of 101 cells counted (R133W) and 108 of 122 (R133A);
corresponding values in CH34 cells were 57 of 69 (R133W) and 114 of 124 (R133A). Similarly, immunoreactive staining in COS-7 cells was
pancellular in 39 of 42 cells counted (R133W) and 21 of 22 (R133A);
corresponding values in CH34 cells were 19 of 21 (R133W) and 19 of 22 (R133A). Any differences in outcome between cell lines (Fig. 3,
A versus B) or among methods of
visualization (Fig. 3, rows a and b
and a' and b') are not of statistical
significance. Impairment of nuclear localization due to mutations R133W
or R133A is in each case similar to that due to deletion of the basic
cluster. Their partial nuclear import presumably reflects continued
activity of the N-terminal NLS.
 |
DISCUSSION |
SRY was originally identified by genetic analysis of patients with
intersex abnormalities (4). In the absence of a priori biochemical information, the mechanism of action of SRY was
hypothesized on the basis of homology between its HMG box and a
conserved family of architectural transcription factors. This
hypothesis has been corroborated in part by a striking correlation
between sites of sex-reversal mutations (3, 6-8) and sites in the HMG
box required for folding or DNA binding (7, 9, 30, 31). Almost all clinical mutations in SRY cluster in the HMG box, and almost all de novo mutations impair DNA binding (9). The present study highlights a mutation in the C-terminal tail of the HMG box (R133W; Ref. 22) that impairs nuclear localization but not DNA binding. The
mutation alters an invariant arginine in a basic cluster previously proposed as an accessory NLS (21). That an alanine substitution likewise impairs nuclear localization suggests that the defect is due
to loss of the basic side chain rather than specific interference by
the bulky Trp-133 side chain. Because alterations in the
C-terminal basic cluster leave intact the N-terminal NLS, effects of
C-terminal substitutions are incomplete, leading to a broad pattern of
cytoplasmic and nuclear localization.
Genetic corroboration of a putative NLS in a transcription factor can
be confounded by the location of such signals within DNA-binding
domains (32, 33). SRY contains NLSs within or adjoining its HMG box
(32, 33). A classical bipartite NLS occurs (19, 20, 34-36) at the N
terminus of the HMG box (11). This region spans the first
-strand
and
-helix (10). Sex-reversal mutations in the N-terminal NLS occur
at arginines (R62G and R76S; Refs. 37 and 38). If these mutations
should impair both DNA binding and nuclear localization (Arg-62
contacts the DNA backbone; Ref. 10), then a selective correlation with
one or the other activities would not be possible. The present study
has focused on the C-terminal basic cluster because its NLS activity
has been inconsistently observed in cell culture (11, 21). We chose to
investigate the sex-reversal mutation R133W because this residue is
disordered both in the SRY·DNA complex (10) and in the homologous lymphoid enhancer factor 1 (Lef-1)·DNA
complex6 (39). We therefore
hypothesized that the de novo substitution might exhibit
native DNA binding properties but impaired nuclear localization.
An extended basic tail in the homologous Lef-1·DNA complex binds
within the compressed major groove (39). The basic side chains not only
provide an NLS (40) but are also proposed to function as an
"electrostatic clamp" to stabilize the sharply bent DNA structure
(39, 41). Truncation of the Lef-1 tail leads to a marked loss of DNA
affinity and marked attenuation in DNA bending (42). It is possible
that an analogous clamp exists in the SRY complex but was not
observable in its NMR structure (10, 43) due to truncation of the
fragment after residue 133 (arrowhead in Fig.
1B). It is interesting that the R133W SRY domain exhibits a
decrement in induced DNA bend angle (Fig. 2D). Perhaps the
several basic residues in the SRY tail together provide an analogous
electrostatic clamp. Although we cannot exclude altered protein-DNA
architecture (44) as a mechanism of R133W-associated sex reversal, the
following considerations suggest that a small decrement in bending is
unlikely to be of physiological significance. (i) Similar such
decrements in Lef-1-induced DNA bending (obtained by variations in its
DNA target site) are not associated with changes in transcriptional
activation in cell culture (42). (ii) Similar such decrements due to
mutations in yeast hypoxic repressor Rox1 (28) (also a specific HMG box
protein) are not associated with changes in transcriptional repression
in vivo; changes in activity correlate instead with specific
DNA affinity. (iii) The R133W-associated decrement is smaller than
variations in bend angle observed among mammalian SRY complexes and in
complexes between human SRY and closely related DNA target sites (27). To our knowledge, no sex-reversal mutation has been identified in SRY
with a selective defect in DNA
bending.7 A physiological
requirement for a sharp DNA bend without precise calibration in
mammalian development would be consistent with studies of bacterial
gene regulation: the 180° "U-turn" bend of initiation host factor
may be functionally replaced by the 130° bend induced by Lef-1 (45,
46). In the future this issue may be explored through studies of the
phenotypes of XX mice engineered to contain Sry transgenes (1) with
mutations in the HMG box designed to affect the bend angles of the
Sry·DNA complex to determine whether sex reversal occurs.
Diverse human diseases are associated with mislocalization of proteins:
impaired display of receptors or channels on the cell surface, impaired
secretion of hormones or growth factors, and impaired nuclear import.
Such abnormalities are often a secondary consequence of other processes
(47). Identification of a primary disorder of localization requires
demonstration of otherwise native biochemical activities. An
outstanding example is provided by a diabetes-associated mutation in
human proinsulin (48, 49). Similarly, primary disorders of nuclear
localization have been proposed in Fanconi anemia (50, 51) and the
Li-Fraumeni (p53) cancer susceptibility syndrome (52-54). Such
mutations affect sites of protein-protein interaction (rather than
primary NLS sequences) required for nuclear import of a cytoplasmic
assembly. To our knowledge, the present study provides the first
example of a mutation in an NLS associated with failure of
organogenesis. Because SOX-9 and SRY contain homologous NLSs (21),
SOX-9 sequences in campomelic dysplasia should be
screened for similar mutations (55, 56, 61). Similar studies of NLS
mutations in cell culture may establish the physiologic relevance of
these and other NLS sequences in disease states.
 |
ACKNOWLEDGEMENTS |
We thank G. Scherer for providing
SRY-
-galactoside fusion plasmids, U. Narendra and N. Phillips for
experimental assistance and communication of unpublished results,
C. M. Haqq and P. K. Donahoe for gonadal cell line CH34, N. Narayana and D. Poruban for preparation of figures, and E. Collins for
assistance with preparation of the manuscript.
 |
FOOTNOTES |
*
This work was supported in part by grants from the March of
Dimes/Birth Defects Foundation and the National Institutes of Health
(to M. A. W.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Present address: Integrated Genomics, 2201 W. Campbell Pkwy.,
Chicago, IL 60615.
§
To whom correspondence should be addressed. Tel.: 216-368-5991;
Fax: 216-368-4458; E-mail: weiss@biochemistry.cwru.edu.
Published, JBC Papers in Press, October 18, 2001, DOI 10.1074/jbc.C100388200
2
Of the greater than 30 clinical mutations found
in SRY to date only four map outside of the HMG box. One is
a familial point mutation N-terminal to the HMG box (S18N) associated
with partial gonadal dysgenesis (57); the second and third are nonsense
mutations at codons 2 and 4 (22, 58), respectively; the fourth causes deletion of the C-terminal 41 residues (59), which includes a
potential PDZ-binding site (11).
3
Although residues in the N-terminal NLS of SRY
contribute to the minor groove DNA-binding surface of the domain, NLS
activity does not require DNA binding: a sex-reversal mutation
elsewhere in the HMG box (Y127C; Fig. 1B) impairs specific
DNA binding but not nuclear localization (11). In the structure of an
SRY·DNA complex (43) Tyr-127 (residue 72) contacts the DNA backbone.
4
It is possible that in a fibroblastic cell line
the C-terminal NLS functions too weakly to be detected given the low
peptide-IgG coupling ratio used in the microinjection assay (11).
5
Inferred DNA bend angles depend somewhat on gel
composition (the present gel system yields an estimate of 79°, for
example, whereas an 8% acrylamide gel with the same ratio of
bisacrylamide yields an estimate of 72°; A. Jancso-Radek and M. A. Weiss, unpublished results). Such apparent effects are thought to
reflect limitations of data analysis (26) rather than physical
differences in DNA bending. Changes in bend angle (
) induced by
native and variant SRY domains are robust to changes in gel composition.
6
The homologous residue in Lef-1 and TCF-1
(autosomal HMG box factors that also regulate organogenesis) is
tyrosine (see Fig. 1B). Although the HMG boxes of both SRY
and Lef-1 are extended by basic tails, the spacing and pattern of basic
residues differ. Unlike Lef-1 and TCF-1 (39), the SRY HMG box retains
high-affinity DNA binding on truncation of the tail. The SRY fragment
used in the NMR analysis of its complex terminated at Arg-133 (43) and so lacked a complete tail.
7
Bianchi and colleagues (44) have suggested that
native DNA bending is required for testicular differentiation. A
de novo sex-reversal mutation (M64I; residue 9 in the HMG
box) was shown in a truncated SRY fragment to impair DNA
bending by 20° but DNA affinity by only 2-fold. This phenotype
was ascribed to the bending defect. By contrast, we have found that the
M64I-associated bending defect is not observed in intact human SRY or
HMG fragments containing an intact tail (A. Jancso-Radek and M. A. Weiss, manuscript in preparation). The defect in the DNA-binding
affinity of the variant is retained.
 |
ABBREVIATIONS |
The abbreviations used are:
HMG, high-mobility
group;
GMSA, gel mobility shift assay;
Lef-1, lymphoid enhancer factor
1;
NLS, nuclear localization signal;
PBS, phosphate-buffered saline;
PGE, permutation gel electrophoresis;
SRY, sex-determining region of Y
chromosome;
TCF-1, T-cell factor 1;
bp, base pair(s);
X-gal, 5-bromo-4-chloro-3-indolyl
-D-galactopyranoside;
WT, wild type.
 |
REFERENCES |
| 1.
|
Koopman, P.,
Gubbay, J.,
Vivian, N.,
Goodfellow, P.,
and Lovell-Badge, R.
(1991)
Nature
351,
117-121[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Gubbay, J.,
Collignon, J.,
Koopman, P.,
Capel, B.,
Economou, A.,
Munsterberg, A.,
Vivian, N.,
Goodfellow, P.,
and Lovell-Badge, R.
(1990)
Nature
346,
245-250[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Berta, P.,
Hawkins, J. R.,
Sinclair, A. H.,
Taylor, A.,
Griffiths, B. L.,
Goodfellow, P. N.,
and Fellous, M.
(1990)
Nature
348,
448-450[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Sinclair, A. H.,
Berta, P.,
Palmer, M. S.,
Hawkins, J. R.,
Griffiths, B. L.,
Smith, M. J.,
Foster, J. W.,
Frischauf, A. M.,
Lovell-Badge, R.,
and Goodfellow, P. N.
(1990)
Nature
346,
240-244[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Ner, S. S.
(1992)
Curr. Biol.
2,
208-210
|
| 6.
|
Nasrin, N.,
Buggs, C.,
Kong, X. F.,
Carnazza, J.,
Goebl, M.,
and Alexander-Bridges, M.
(1991)
Nature
354,
317-320[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Harley, V. R.,
Jackson, D. I.,
Hextall, P. J.,
Hawkins, J. R.,
Berkovitz, G. D.,
Sockanathan, S.,
Lovell-Badge, R.,
and Goodfellow, P. N.
(1992)
Science
255,
453-456[Abstract/Free Full Text]
|
| 8.
|
Hawkins, J. R.,
Taylor, A.,
Berta, P.,
Levilliers, J.,
Van der Auwera, B.,
and Goodfellow, P. N.
(1992)
Hum. Genet.
88,
471-474[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Haqq, C. M.,
King, C. Y.,
Ukiyama, E.,
Falsafi, S.,
Haqq, T. N.,
Donahoe, P. K.,
and Weiss, M. A.
(1994)
Science
266,
1494-1500[Abstract/Free Full Text]
|
| 10.
|
Werner, M. H.,
Huth, J. R.,
Gronenborn, A. M.,
and Clore, G. M.
(1995)
Cell
81,
705-714[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Poulat, F.,
Girard, F.,
Chevron, M. P.,
Goze, C.,
Rebillard, X.,
Calas, B.,
Lamb, N.,
and Berta, P.
(1995)
J. Cell Biol.
128,
737-748[Abstract/Free Full Text]
|
| 12.
|
Koopman, P.,
Munsterberg, A.,
Capel, B.,
Vivian, N.,
and Lovell-Badge, R.
(1990)
Nature
348,
450-452[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Lovell-Badge, R.
(1993)
Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci.
339,
159-164[Medline]
[Order article via Infotrieve]
|
| 14.
|
Hanley, N. A.,
Hagan, D. M.,
Clement-Jones, M.,
Ball, S. G.,
Strachan, T.,
Salas-Cortes, L.,
McElreavey, K.,
Lindsay, S.,
Robson, S.,
Bullen, P.,
Ostrer, H.,
and Wilson, D. I.
(2000)
Mech. Dev.
91,
403-407[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Dubin, R. A.,
and Ostrer, H.
(1994)
Mol. Endocrinol.
8,
1182-1192[Abstract]
|
| 16.
|
Cohen, D. R.,
Sinclair, A. H.,
and McGovern, J. D.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
4372-4376[Abstract/Free Full Text]
|
| 17.
|
Koopman, P.
(2001)
EXS (Basel)
91,
25-56
|
| 18.
|
Salas-Cortes, L.,
Jaubert, F.,
Barbaux, S.,
Nessmann, C.,
Bono, M. R.,
Fellous, M.,
McElreavey, K.,
and Rosemblatt, M.
(1999)
Int. J. Dev. Biol.
43,
135-140[Medline]
[Order article via Infotrieve]
|
| 19.
|
Robbins, J.,
Dilworth, S. M.,
Laskey, R. A.,
and Dingwall, C.
(1991)
Cell
64,
615-623[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Boulikas, T.
(1993)
Crit. Rev. Eukaryot. Gene Expr.
3,
193-227[Medline]
[Order article via Infotrieve]
|
| 21.
|
Sudbeck, P.,
and Scherer, G.
(1997)
J. Biol. Chem.
272,
27848-27852[Abstract/Free Full Text]
|
| 22.
|
Veitia, R.,
Ion, A.,
Barbaux, S.,
Jobling, M. A.,
Souleyreau, N.,
Ennis, K.,
Ostrer, H.,
Tosi, M.,
Meo, T.,
Chibani, J.,
Fellous, M.,
and McElreavey, K.
(1997)
Hum. Genet.
99,
648-652[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
King, C. Y.,
and Weiss, M. A.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
11990-11994[Abstract/Free Full Text]
|
| 24.
|
Haqq, C. M.,
King, C. Y.,
Donahoe, P. K.,
and Weiss, M. A.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
1097-1101[Abstract/Free Full Text]
|
| 25.
|
Kim, J.,
Zwieb, C.,
Wu, C.,
and Adhya, S.
(1989)
Gene (Amst.)
85,
15-23[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Ferrari, S.,
Harley, V. R.,
Pontiggia, A.,
Goodfellow, P. N.,
Lovell-Badge, R.,
and Bianchi, M. E.
(1992)
EMBO J.
11,
4497-4506[Medline]
[Order article via Infotrieve]
|
| 27.
|
Giese, K.,
Kingsley, C.,
Kirshner, J. R.,
and Grosschedl, R.
(1995)
Genes Dev.
9,
995-1008[Abstract/Free Full Text]
|
| 28.
|
Deckert, J.,
Khalaf, R. A.,
Hwang, S. M.,
and Zitomer, R. S.
(1999)
Nucleic Acids Res.
27,
3518-3526[Abstract/Free Full Text]
|
| 29.
|
Ukiyama, E.,
Jancso-Radek, A.,
Li, B.,
Milos, L.,
Zhang, W.,
Phillips, N. B.,
Morikawa, N.,
King, C. Y.,
Chan, G.,
Haqq, C. M.,
Radek, J. T.,
Poulat, F.,
Donahoe, P. K.,
and Weiss, M. A.
(2001)
Mol. Endocrinol.
15,
363-377[Abstract/Free Full Text]
|
| 30.
|
Giese, K.,
Amsterdam, A.,
and Grosschedl, R.
(1991)
Genes Dev.
5,
2567-2578[Abstract/Free Full Text]
|
| 31.
|
Lorenz, M.,
Hillisch, A.,
Payet, D.,
Buttinelli, M.,
Travers, A.,
and Diekmann, S.
(1999)
Biochemistry
38,
12150-12158[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Vandromme, M.,
Cavadore, J. C.,
Bonnieu, A.,
Froeschle, A.,
Lamb, N.,
and Fernandez, A.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
4646-4650[Abstract/Free Full Text]
|
| 33.
|
Henkel, T.,
Zabel, U.,
van Zee, K.,
Muller, J. M.,
Fanning, E.,
and Baeuerle, P. A.
(1992)
Cell
68,
1121-1133[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Kalderon, D.,
Roberts, B. L.,
Richardson, W. D.,
and Smith, A. E.
(1984)
Cell
39,
499-509[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Conti, E.,
Uy, M.,
Leighton, L.,
Blobel, G.,
and Kuriyan, J.
(1998)
Cell
94,
193-204[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Hodel, M. R.,
Corbett, A. H.,
and Hodel, A. E.
(2000)
J. Biol. Chem.
276,
1317-1325[Abstract/Free Full Text]
|
| 37.
|
Affara, N. A.,
Chalmers, I. J.,
and Ferguson-Smith, M. A.
(1993)
Hum. Mol. Genet.
2,
785-789[Abstract/Free Full Text]
|
| 38.
|
Imai, A.,
Takagi, A.,
and Tamaya, T.
(1999)
Endocr. J.
46,
735-739[Medline]
[Order article via Infotrieve]
|
| 39.
|
Love, J. J.,
Li, X.,
Case, D. A.,
Giese, K.,
Grosschedl, R.,
and Wright, P. E.
(1995)
Nature
376,
791-795[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Prieve, M. G.,
Guttridge, K. L.,
Munguia, J. E.,
and Waterman, M. L.
(1996)
J. Biol. Chem.
271,
7654-7658[Abstract/Free Full Text]
|
| 41.
|
Lnenicek-Allen, M.,
Read, C. M.,
and Crane-Robinson, C.
(1996)
Nucleic Acids Res.
24,
1047-1051[Abstract/Free Full Text]
|
| 42.
|
Giese, K.,
Pagel, J.,
and Grosschedl, R.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
12845-12850[Abstract/Free Full Text]
|
| 43.
|
Werner, M. H.,
Bianchi, M. E.,
Gronenborn, A. M.,
and Clore, G. M.
(1995)
Biochemistry
34,
11998-12004[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Pontiggia, A.,
Whitfield, S.,
Goodfellow, P. N.,
Lovell-Badge, R.,
and Bianchi, M. E.
(1995)
Gene (Amst.)
2,
277-280
|
| 45.
|
Segall, A. M.,
Goodman, S. D.,
and Nash, H. A.
(1994)
EMBO J.
13,
4536-4548[Medline]
[Order article via Infotrieve]
|
| 46.
|
Parekh, B. S.,
and Hatfield, G. W.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
1173-1177[Abstract/Free Full Text]
|
| 47.
|
Soutar, A. K.
(1998)
Curr. Opin. Lipidol.
9,
141-147[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Burke, G. T.,
Schwartz, G.,
and Katsoyannis, P. G.
(1984)
Int. J. Pept. Protein Res.
23,
394-401[Medline]
[Order article via Infotrieve]
|
| 49.
|
Chan, S. J.,
Seino, S.,
Gruppuso, P. A.,
Schwartz, R.,
and Steiner, D. F.
(1987)
Proc. Natl. Acad. Sci.
84,
2194-2197[Abstract/Free Full Text]
|
| 50.
|
Naf, D.,
Kupfer, G. M.,
Suliman, A.,
Lambert, K.,
and D'Andrea, A. D.
(1998)
Mol. Cell. Biol.
18,
5952-5960[Abstract/Free Full Text]
|
| 51.
|
Garcia-Higuera, I.,
Kuang, Y.,
and D'Andrea, A. D.
(1999)
Curr. Opin. Hematol.
6,
83-88[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Shaulsky, G.,
Goldfinger, N.,
Tosky, M. S.,
Levine, A. J.,
and Rotter, V.
(1991)
Oncogene
6,
2055-2065[Medline]
[Order article via Infotrieve]
|
| 53.
|
Liang, S. H.,
and Clarke, M. F.
(1999)
J. Biol. Chem.
274,
32699-32703[Abstract/Free Full Text]
|
| 54.
|
Gu, J.,
Kawai, H.,
Wiederschain, D.,
and Yuan, Z. M.
(2001)
Cancer Res.
61,
1741-1746[Abstract/Free Full Text]
|
| 55.
|
Foster, J. W.,
Dominguez-Steglich, M. A.,
Guioli, S.,
Kowk, G.,
Weller, P. A.,
Stevanovic, M.,
Weissenbach, J.,
Mansour, S.,
Young, I. D.,
Goodfellow, P. N.,
Brook, J. D.,
and Schafer, A. J.
(1994)
Nature
372,
525-530[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Wagner, T.,
Wirth, J.,
Meyer, J.,
Zabel, B.,
Held, M.,
Zimmer, J.,
Pasantes, J.,
Bricarelli, F. D.,
Keutel, J.,
Hustert, E.,
Wolf, U.,
Tommerup, N.,
Schempp, W.,
and Scherer, G.
(1994)
Cell
79,
1111-1120[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Domenice, S.,
Yumie Nishi, M.,
Correia Billerbeck, A. E.,
Latronico, A. C.,
Aparecida Medeiros, M.,
Russell, A. J.,
Vass, K.,
Marino Carvalho, F.,
Costa Frade, E. M.,
Prado Arnhold, I. J.,
and Bilharinho Mendonca, B.
(1998)
Hum. Genet.
102,
213-215[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Brown, S., Yu, C.,
Lanzano, P.,
Heller, D.,
Thomas, L.,
Warburton, D.,
Kitajewski, J.,
and Stadtmauer, L.
(1998)
Am. J. Hum. Genet.
62,
189-192[CrossRef][Medline]
[Order article via Infotrieve]
|
| 59.
|
Tajima, T.,
Nakae, J.,
Shinohara, N.,
and Fujieda, K.
(1994)
Hum. Mol. Genet.
3,
1187-1189[Free Full Text]
|
| 60.
|
Teo, S. H.,
Grasser, K. D.,
and Thomas, J. O.
(1995)
Eur. J. Biochem.
3,
943-950
|
| 61.
|
Preiss, S.,
Argentaro, A.,
Clayton, A.,
John, A.,
Jans, D. A.,
Ogata, T.,
Nagai, T.,
Barroso, I.,
Schafer, A. J.,
and Harley, V. R.
(2001)
J. Biol. Chem.
276,
27864-27872[Abstract/Free Full Text]
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. E.J. Bedard, J. D. Purnell, and S. M. Ware
Nuclear import and export signals are essential for proper cellular trafficking and function of ZIC3
Hum. Mol. Genet.,
January 15, 2007;
16(2):
187 - 198.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. R. Harley, S. Layfield, C. L. Mitchell, J. K. Forwood, A. P. John, L. J. Briggs, S. G. McDowall, and D. A. Jans
Defective importin {beta} recognition and nuclear import of the sex-determining factor SRY are associated with XY sex-reversing mutations
PNAS,
June 10, 2003;
100(12):
7045 - 7050.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Qin, W. Kang, B. Leung, and M. McLeod
Ste11p, a High-Mobility-Group Box DNA-Binding Protein, Undergoes Pheromone- and Nutrient-Regulated Nuclear-Cytoplasmic Shuttling
Mol. Cell. Biol.,
May 1, 2003;
23(9):
3253 - 3264.
[Abstract]
[Full Text]
[PDF]
|
 |
|